Drug intelligence / Profile preview

68Ga-THP-Trop2 VHH

Development stage: Unknown
Lead developer: First Affiliated Hospital of Xiamen University
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-THP-Trop2 VHH is an investigational ImmunoPET radiotracer designed for the non-invasive imaging of Trophoblast Cell-Surface Antigen 2 (Trop-2) expression in solid tumors. The agent consists of a Gallium-68 (^68Ga) radioisotope complexed with a tris(hydroxypyridinone) (THP) chelator, which is conjugated to a VHH (variable domain of heavy-chain only antibody), also known as a nanobody, specific for Trop-2. Trop-2 is a transmembrane glycoprotein frequently overexpressed in epithelial cancers and is a primary target for antibody-drug conjugates (ADCs). The use of a VHH allows for rapid blood clearance and high-contrast imaging due to its small size compared to full-length antibodies. The THP chelator facilitates rapid, one-step radiolabeling with Gallium-68 under mild conditions, making it suitable for clinical diagnostic workflows to identify patients who may benefit from Trop-2-targeted therapies.

Other names: 68Ga-THP-Trop2-VHHgallium Ga-68 THP-Trop2 VHH68Ga-THP-anti-Trop-2 VHH

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on 68Ga-THP-Trop2 VHH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-THP-Trop2 VHH.

Explore the full profile